PFIZER INC Reports Unchanged Revenue for Third Quarter of FY2023

November 20, 2023

🌥️Earnings Overview

For the third quarter of FY2023 (ending September 30 2023), PFIZER INC ($NYSE:PFE) reported total revenue of USD 13232.0 million and net income of USD -2382.0 million, both figures remaining unchanged from the same quarter of the prior fiscal year.

Market Price

The stock opened at $30.9, but closed at $30.8, down by 1.4% from its prior closing price of 31.2. This marks a decrease in the stock price from the beginning of the day and is indicative of investor sentiment towards the company’s financial performance. Despite the fact that total revenue remained unchanged, there were some positive indicators to be seen in the company’s financials. Operating income and net income both increased compared to the prior quarter, suggesting that PFIZER INC is focusing on cost control and effective management of their resources.

These improvements in their bottom line despite unchanged revenue have been welcomed by investors. Overall, the financial results for the third quarter of FY2023 suggest that PFIZER INC’s business remains stable, although investors remain cautious about the company’s future prospects. Investors will likely be closely watching the company’s performance in the coming quarters to see if they can build upon these promising results or if they will slip back into stagnation. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Pfizer Inc. More…

    Total Revenues Net Income Net Margin
    68.54k 10.48k 18.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Pfizer Inc. More…

    Operations Investing Financing
    29.27k -15.78k -14.83k
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…

    Total Assets Total Liabilities Book Value Per Share
    197.21k 101.29k 16.94
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Pfizer Inc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    12.1% -6.5% 17.9%
    FCF Margin ROE ROA
    38.0% 8.0% 3.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale’s analysis of PFIZER INC‘s wellbeing has revealed that it has a high health score of 8/10 in terms of cashflows and debt, making it capable of riding out any crisis without the risk of bankruptcy. Furthermore, its classification as a ‘cow’ type of company indicates that it is likely to have a track record of paying out consistent and sustainable dividends. This makes it an attractive investment opportunity for investors looking for a steady income stream. PFIZER INC is strong in dividend, profitability, but only medium in asset and weak in growth. It thus does not provide immediate gains for investors, but it is a safe and reliable option for long-term growth. Investors who prefer low-risk investments may find PFIZER INC to be the right choice for them. More…

  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.

    – Astellas Pharma Inc ($TSE:4503)

    Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.

    – Roche Holding AG ($OTCPK:RHHBY)

    Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”

    Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.

    – AstraZeneca PLC ($LSE:AZN)

    AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.


    Pfizer Inc‘s third quarter earnings report for FY2023 showed total revenue of USD 13232.0 million, unchanged from the same period in the prior year. Net income was reported at USD -2382.0 million, also unchanged year over year. Although revenue remained flat, the lack of growth in net income could be a discouraging sign for long-term investors, suggesting that the company may not be able to achieve high-level profitability in the future. Short-term investors may take advantage of the current situation, as Pfizer Inc’s stock may be undervalued due to the lack of growth.

    However, investors should take into consideration the overall macroeconomic environment and the potential for future uncertainty when making investing decisions.

    Recent Posts

    Leave a Comment